Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alastair M Thompson

Showing results (121-130 of 195) with videos related to

Pageof 20
Sort By:
BMJ Open|April 20, 2024
Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT projectShelley Potter, Kerry Avery, Rosina Ahmed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2025
Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline UpdateKo Un Park, Mark R Somerfield, Nirupama Anne, et al.
Ultrasound in Medicine & Biology|March 18, 2022
Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast CancerRosalind P Candelaria, Beatriz E Adrada, Deanna L Lane, et al.
European Journal of Radiology|August 11, 2020
Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patientsRosalind P Candelaria, Beatriz E Adrada, Kenneth Hess, et al.
Annals of Surgical Oncology|July 27, 2025
Patient-reported Outcomes After Routine Treatment of In Situ/Atypical Lesions: The PORTAL StudyShoshana M Rosenberg, Christel Rushing, Kristin L Schreiber, et al.
Lancet (London, England)|February 1, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trialJanet A Dunn, Peter Donnelly, Nada Elbeltagi, et al.
The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
British Journal of Cancer|May 17, 2024
Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancerWarapen Treekitkarnmongkol, Vandna Shah, Kazuharu Kai, et al.
European Journal of Radiology|February 22, 2022
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancerJorge E Jimenez, Abeer Abdelhafez, Elizabeth A Mittendorf, et al.
JNCI Cancer Spectrum|September 6, 2021
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs PlaceboPamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
Pageof 20

Showing results (121-130 of 195) with videos related to

Sort By:
Pageof 20
BMJ Open|April 20, 2024
Protocol for the development of a core outcome set and reporting guidelines for locoregional treatment in neoadjuvant systemic breast cancer treatment trials: the PRECEDENT projectShelley Potter, Kerry Avery, Rosina Ahmed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2025
Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline UpdateKo Un Park, Mark R Somerfield, Nirupama Anne, et al.
Ultrasound in Medicine & Biology|March 18, 2022
Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast CancerRosalind P Candelaria, Beatriz E Adrada, Deanna L Lane, et al.
European Journal of Radiology|August 11, 2020
Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patientsRosalind P Candelaria, Beatriz E Adrada, Kenneth Hess, et al.
Annals of Surgical Oncology|July 27, 2025
Patient-reported Outcomes After Routine Treatment of In Situ/Atypical Lesions: The PORTAL StudyShoshana M Rosenberg, Christel Rushing, Kristin L Schreiber, et al.
Lancet (London, England)|February 1, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trialJanet A Dunn, Peter Donnelly, Nada Elbeltagi, et al.
The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
British Journal of Cancer|May 17, 2024
Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancerWarapen Treekitkarnmongkol, Vandna Shah, Kazuharu Kai, et al.
European Journal of Radiology|February 22, 2022
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancerJorge E Jimenez, Abeer Abdelhafez, Elizabeth A Mittendorf, et al.
JNCI Cancer Spectrum|September 6, 2021
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs PlaceboPamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
Pageof 20